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Resveratrol is a polyphenolic phytoestrogen that has been
shown to exhibit potent anti-oxidant, anti-inflammatory, and
anti-catabolic properties. Increased osteoclastic and decreased
osteoblastic activities result in bone resorption and loss of bone
mass. These changes have been implicated in pathological pro-
cesses in rheumatoid arthritis and osteoporosis. Receptor acti-
vator of NF-B ligand (RANKL), a member of the TNF super-
family, is a major mediator of bone loss. In this study, we
investigated the effects of resveratrol on RANKL during bone
morphogenesis in high density bone cultures in vitro. Untreated
bone-derived cell cultures produced well organized bone-like
structures with a bone-specific matrix. Treatment with RANKL
induced formation of tartrate-resistant acid phosphatase-posi-
tive multinucleated cells that exhibited morphological features
of osteoclasts. RANKL induced NF-B activation, whereas pre-
treatment with resveratrol completely inhibited this activation
and suppressed the activation of IB kinase and IB phos-
phorylation and degradation. RANKL up-regulated p300 (a his-
tone acetyltransferase) expression, which, in turn, promoted
acetylation of NF-B. Resveratrol inhibited RANKL-induced
acetylation and nuclear translocation of NF-B in a time- and
concentration-dependent manner. In addition, activation of
Sirt-1 (a histone deacetylase) by resveratrol induced Sirt-1-p300
association in bone-derived and preosteoblastic cells, leading to
deacetylation of RANKL-induced NF-B, inhibition of NF-B
transcriptional activation, and osteoclastogenesis. Co-treat-
ment with resveratrol activated the bone transcription factors
Cbfa-1 and Sirt-1 and induced the formation of Sirt-1-Cbfa-1
complexes. Overall, these results demonstrate that resveratrol-
activated Sirt-1 plays pivotal roles in regulating the balance
between the osteoclastic versus osteoblastic activity result in
bone formation in vitro thereby highlighting its therapeutic
potential for treating osteoporosis and rheumatoid arthritis-re-
lated bone loss.
Bone connective tissue has a highly specific architecture,
two-thirds of which is composed of inorganic material and the
remainder is organic material, including extracellular matrix
proteins and the cells forming the bone-specific extracellular
matrix and water (1). It is very important in bone tissue to
maintain the architectural stability, morphology, and composi-
tion of the calcified structures. Bone contains three principal
cell types that are responsible for maintaining the following
functions: bone-synthesizing osteoblasts, bone-resident osteo-
cytes, and bone-resorbing osteoclasts and undifferentiated
mesenchymal cells. Remodeling and maintenance of bone tis-
sue are regulated through bone extracellular matrix synthesis
by osteoblasts and extracellular matrix resorption by oste-
oclasts (2). Under physiological conditions, a delicate equilib-
rium exists between new bone synthesis and old bone resorp-
tion. However, in pathological conditions such as rheumatoid
arthritis and osteoporosis, this fine balance between synthesis
and degradation goes astray resulting in excessive loss of bone
mineral density and extracellular matrix degradation exacer-
bating osteoporosis and rheumatoid arthritis-related bone loss
(3).
Osteoclasts are multinucleated cells formed by the fusion of
hematopoietic lineage-derived monocytes-macrophages in
bone marrow (4). They are phenotypically characterized by
high production of tartrate-resistant acid phosphatase (TRAP)3
and cathepsin K (5). Numerous factors have been reported to
induce osteoclast activation, including receptor activator of
nuclear factor B ligand (RANKL), tumor necrosis factor-
(TNF-), interleukin-1 (IL-1), and macrophage colony-
stimulating factor (M-CSF) (6–9). RANKL is a member of the
TNF superfamily and is produced by osteoblasts and bone
marrow stromal cells (10–12). Its receptor RANK is
expressed on the surface of preosteoclasts and plays impor-
tant roles during osteoclastogenesis (13). RANK acts as a
receptor for RANKL and osteoprotegerin, a soluble receptor,
produced by osteoblasts. RANK and osteoprotegerin can
bind RANKL and control osteoclast formation (14–17). It
has been shown that RANKL knock-out mice possess an
osteopetrotic phenotype with dentition defects, cartilage
destruction, and bone erosion and exhibit a deficiency of
osteoclasts (18). Furthermore, RANKL is able to stimulate
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osteoclasts and can cause the resorption of bone mass in vivo
by activating preosteoclasts (10, 11). RANKL is essential for
bone remodeling and plays an important role in mature oste-
oclast survival (10).
The transcriptional co-activator p300 is a histone acetyl-
transferase (19, 20). It serves to integrate signaling pathways
involved in diverse cellular functions (21). This protein pro-
motes histone acetylation and regulates promoter activity by
removing chromatin-dependent repression (22). Furthermore,
it acetylates a number of transcriptional factors (e.g. p53,
FOXO-1, E2F, and HMG I) resulting in transcriptional regula-
tion (23–25). It has been reported that p300 acetyltransferase
acetylates NF-B-p65 (at lysine 310) (26) that, in turn, activates
NF-B-specific transcriptional activity and up-regulates the
expression of the anti-apoptotic genes of the Bcl-2 family, such
as Bcl-xL (27, 28).
The bone transcription factor Cbfa-1 (core binding factor
-1) is one of the earliest and most specific markers of osteo-
genesis (29). Cbfa-1 acts as an activator of transcription and
can induce osteoblast-specific gene expression in vitro (29).
Mechanical signals can regulate Cbfa-1 activation favoring
osteoblast differentiation through the activation of the
MAPK signal transduction pathway and Ras/Raf-dependent
Erk1/2 activation, independent of p38 MAPK signaling (30).
The polyphenolic and phytoestrogenic plant resveratrol
(trans-3,4-trihydroxystilbene) naturally occurs in the skin of
red grapes, vines, various other fruits, peanuts, and root
extracts of the weed Polygonum cuspidatum (31). In plants,
resveratrol protects against fungal infections and exhibits anti-
protozoal activity (32). Resveratrol also has potent anti-inflam-
matory, anti-tumor, immunomodulatory, cardioprotective,
anti-oxidative, and chemopreventive properties (33, 34). How-
ever, its effects on osteoclast differentiation have not been eval-
uated thus far. Resveratrol can inhibit NF-B activation and
down-regulate the proinflammatory gene products COX-2,
IL-1, and IL-6, which play important roles in various forms of
arthritis (35, 36). We have recently shown that resveratrol
exerts anti-apoptotic, anti-oxidative, anti-tumor suppressor
protein p53, and anti-inflammatory functions in chondrocytes
(37–39). These chemopreventive properties of resveratrol have
been associated with the inhibition of NF-B. Furthermore,
resveratrol is a potent activator of the Sirt-1/Sir2 (silent infor-
mation regulator 2) family of NAD-dependent histone deacety-
lases (40). These deacetylases remove the acetyl group from
acetyl-lysine in histones and non-histone substrates, such as
transcription factors and co-activators of transcription and
cytoplasmic proteins (41), subsequently causing widespread
effects on cell function (42). Several studies have shown that
many of the beneficial effects of resveratrol are due to acti-
vation of Sirt-1, including stress resistance and life span
extension (40). Although resveratrol is a potent inhibitor of
NF-B, its effects on osteoblasts and osteoclasts have not yet
been fully investigated at the cellular or molecular levels.
Because phytoestrogens are known to affect the biology of
osteoblasts and osteoclasts, and osteoblasts regulate oste-
oclast activity through the expression of RANKL, we evalu-




Antibodies to -actin were obtained from Sigma. Antibodies
against p65, pan-IB, and TRAP were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA). Antibodies against
phospho-specific IB (Ser-32/36) and anti-phospho-specific
p65 (Ser-536) were obtained from Cell Technology (Beverly,
MA). Anti-IB kinase (IKK)- and anti-IKK- antibodies
were obtained from Imgenex (Germany). Monoclonal anti-
Sirt-1 antibody (Ab 12193) was purchased from Abcam. Poly-
clonal anti-Cbfa-1 (CBFA11-A) was purchased from Alpha
Diagnostic International Inc., San Antonio, TX. Monoclonal
anti-poly(ADP-ribose) polymerase antibody was purchased
from BD Biosciences. Acetylated lysine (Ac-K-103) antibody
was purchased fromCell Signaling Technology (Danvers, MA).
Anti-p300 antibodywas purchased fromMillipore.All antibod-
ies were used at concentrations and dilutions recommended by
the manufacturer (dilutions ranged from 1:100 for immuno-
morphological experiments to 1:10,000 for Western blot
analysis).
Growth Media, Chemicals, and Cytokines—Growth medium
(Ham’s F-12/Dulbecco’s modified Eagle’s medium (50:50) con-
taining 10% fetal calf serum (FCS), 25 g/ml ascorbic acid, 50
IU/ml streptomycin, 50 IU/ml penicillin, 2.5 g/ml amphoter-
icin B, essential amino acids and L-glutamine) was obtained
from Seromed (Munich, Germany). Trypsin/EDTA (EC
3.4.21.4) was purchased from Sigma. Epon was obtained from
Plano (Marburg, Germany). RANKL was purchased from R&D
Systems (Abingdon, UK).
Resveratrol with purity greater than 98%was purchased from
Sigma. A 100 mM stock solution of resveratrol (molecular
weight, 228.2) was prepared in ethanol and further diluted in
cell culture medium for working concentrations. The maxi-
mum final concentration of ethanol in culture was less than
0.1% and had no cytotoxic effects.
IL-1 was obtained from Acris Antibodies GmbH (Herold,
Germany). Peptide aldehydes and a specific proteasome inhib-
itor N-Ac-Leu-Leu-norleucinal were obtained from Roche
Applied Science. For osteoclast differentiation, bone-derived
cells were suspended in growth medium supplemented with
10% FCS and 100 ng/ml (5 nM) RANKL.
Primary Bone-derived Cell Isolation and Culture—Canine
bone fragments were cut from femoral heads obtained during
total hip replacement surgery with fully informed owner con-
sent and ethical project approval from the ethical review com-
mittee of Ludwig-Maximilians-University, Munich, Germany.
Bone-derived cells used in the experiments described were
always from the same animal. The experimentswere performed
a total of three times, and samples from three different donors
were used in each experiment. Donor ages ranged from 5 to 7
years. Care was taken to isolate bone fragments only from the
inner trabecular bone to avoid contaminationwith soft or other
fibrous tissues. The 5–10 bone fragments of 3–4-mm were
plated per 35-mmPetri dish in 10ml of cell culturemediumand
incubated at 37 °C, 5% CO2. After 1–2 weeks, bone cells
migrated from the bone fragments and adhered to the cell cul-
ture dish. After colonies reached confluency, the cells were
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trypsinized. Primary isolated bone tissue cells were passaged
2–3 times to gain sufficient cells for the preparation of high
density cultures.
Preosteoblastic Cell Line Culture—The mouse preosteoblas-
tic MC3T3-E1 (DSMZ, Braunschweig, Germany) was selected
as an in vitro model of preosteoblastic cells. The cells were
cultured in -minimal essential medium containing 10% FBS,
100 units/ml penicillin, and 100mg/ml streptomycin. The cells
were maintained in a humidified, 95% air, 5% CO2 atmosphere
at 37 °C. All experiments were performed with third passage
MC3T3-E1 cells.
Experimental Design
High Density Cultures—Primary isolated bone tissue cells
were cultivated in high density cultures. The cells were either
left untreated, treated with 10 nM RANKL alone for the indi-
cated time periods, or pretreated with 5 M resveratrol for 4 h
followed by co-treatmentwith 10 nMRANKL and 5M resvera-
trol for the indicated time periods. High density cultures were
performed as described previously (43). Briefly, high density
cultures were established by adding the cells onto a nitrocellu-
lose filter, which was placed on a steel net bridge. Approxi-
mately 8 l of cell suspension, containing 1 million cells, and
after 1 day in culture, this aggregated into a cell pellet. High
density cultures were incubated with osteogenic induction
medium. The osteogenic induction medium was prepared as
described previously (44); it consisted of DMEM as a base
medium, 10% FCS, penicillin/streptomycin solution (10,000
IU/10,000 IU/100 ml), 107 M dexamethasone (Sigma, catalog
no. D-8893), 10 mM -glycerophosphate (Sigma, catalog no.
G-9891), and 50 M ascorbate 2-phosphate (Sigma, catalog no.
A-8960). Cells were nurtured through diffusion at the filter
medium interface and evaluated after 3, 7, 10, and 14 days.
Monolayer Cultures—For investigation of NF-B transloca-
tion and IB phosphorylation, primary bone tissue cell mono-
layer cultures were washed three times with serum-starved
medium and incubated for 1 hwith serum-starvedmedium (3%
FCS) either treated with 5 M resveratrol or 10 nM RANKL or
co-treatedwith 10nMRANKLand5Mresveratrol for 0, 10, 20,
30, 40, and 60 min, and nuclear and cytoplasmic extracts were
prepared. These experiments were performed in triplicate, and
the results are provided asmean values from three independent
experiments.
For induction of the osteoblast phenotype, the MC3T3-E1
cells at 80% confluence were cultured in differentiation
medium (-minimal essential medium containing 10% FBS, 10
mM -glycerol phosphate, and 50 mg/ml L-ascorbic acid) for 3
days (45). For investigation of resveratrol-promoted osteo-
genesis, the MC3T3-E1 cells were either left untreated or
treated with 5 M resveratrol or 10 nM RANKL for 1 h or
pretreated with 5 M resveratrol for 1 h followed by 3 days
co-treatment with 10 nM RANKL and 5 M resveratrol.
Immunofluorescence Microscopy—Immunofluorescence
studies of primary bone tissue cells were carried out as
described previously (38). Briefly, bone cells were seeded on
glass plates and incubated with osteogenic medium. After 24 h,
the cells were treated with or without RANKL (10 mM) or pre-
treated with resveratrol (5 M) for 4 h and co-treated with
RANKL (10 mM) for the indicated time. Cultures were immu-
nolabeled against TRAP and examined under a fluorescent
microscope (Axiophot 100, Zeiss, Germany).
Transmission Electron Microscopy—Samples were fixed 1 h
with Karnovsky’s fixative followed by post-fixation in 1% OsO4
solution (0.1 M phosphate buffer). Monolayer cell pellets were
rinsed and dehydrated in an ascending alcohol series before
being embedded in Epon and cut on a Reichert-Jung Ultracut E
(Germany). Ultrathin sections were contrasted with 2% uranyl
acetate/lead citrate. A transmission electronmicroscope (TEM
10, Zeiss, Jena, Germany) was used to examine the cultures.
Quantification ofMultinucleatedOsteoclast Cells—Toquan-
tify the multinucleated osteoclasts, the number of cells exhibit-
ing typical morphological features of multinucleated cells was
determined by scoring 100 cells from 30 different microscopic
fields per culture, and the number of multinucleated cells was
expressed as an indicator of osteoclastogenesis.
Immunoelectron Microscopy (Post-embedding Technique)—
Immunoelectron microscopy was performed as described pre-
viously in detail (46). Briefly, cultures were fixed for 1 h in 3%
freshly prepared formaldehyde (paraformaldehyde plus 0.25%
glutaraldehyde), washed three times with 0.1 M PBS, dehy-
drated in an ascending series of alcohol baths, and embedded in
LR-white (Plano,Marburg, Germany). Ultrathin sections of the
cultures were prepared and treated as follows: 1% BSA at ambi-
ent temperature (AT) for 30 min; testicular chondroitinase
(5000 units/ml) for 5 min to unmask antigen epitopes; 1% PBS/
BSA and 0.5% Tween 20 two times for 5 min at AT; primary
antibodies (diluted 1:50 in 1% PBS/BSA) overnight at 4 °C; 1%
PBS/BSA two times for 5min at AT; secondary antibodies con-
jugated with goat anti-rabbit immunoglobulin with 10-nm gold
particles (1:50 for 30min) at AT; and after rinsing two times for
5min at AT, contrastingwas carried out with 1% tannic acid for
20min atAT,with 4%osmium tetroxide for 10min andwith 2%
uranyl acetate for 30 min. Finally, the sections were rinsed and
examined under a transmission electron microscope (Zeiss,
Germany).
Preparation of Nuclear Extracts from Bone Tissue Cells—
Cells were trypsinized andwashed twice in 1ml of ice-cold PBS.
The supernatant was carefully removed. The cell pellet was
resuspended in 400 l of hypotonic lysis buffer containing pro-
tease inhibitors and incubated on ice for 15 min. 12.5 l of 10%
Nonidet P-40 were added, and the cell suspension was vigor-
ously mixed for 15 s. The extracts were centrifuged for 1.5 min.
The supernatants (cytoplasmic extracts) were frozen at70 °C.
25 l of ice-cold nuclear extraction buffer was added to the
pellets and incubated for 30 min with intermittent mixing.
Extracts were centrifuged, and the supernatant (nuclear
extracts) was transferred to prechilled tubes for storage at
70 °C.
Immune Complex Kinase Assay—To test the effect of res-
veratrol on RANKL-induced IKK activation, immune complex
kinase assays were performed. Immune complex kinase assays
were performed as described previously (47). The IKK complex
was immunoprecipitated from whole cell lysates with antibod-
ies against IKK- and IKK- and subsequently incubated with
proteinA/G-agarose beads (Pierce). After 2 h of incubation, the
beadswerewashedwith lysis buffer and resuspended in a kinase
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assay solution containing 50 mM HEPES (pH 7.4), 20 mM
MgCl2, 2 mM dithiothreitol, 10 M unlabeled ATP, and 2 mg of
substrate GST-IB (amino acid 1–54) and incubated at 30 °C
for 30 min. This was followed by boiling in SDS-PAGE sample
buffer for 5 min. The proteins were transferred to a nitrocellu-
lose membrane after SDS-PAGE under reducing conditions as
described above. Phosphorylation of GST-IB was assessed
using a specific antibody against phospho-specific IB (Ser-
32/36). To demonstrate the total amounts of IKK- and IKK-
in each sample, whole cell lysates were transferred to a nitro-
cellulose membrane after SDS-PAGE under reducing condi-
tions as described above. Detection of IKK- and IKK- was
performed by immunoblotting with either anti-IKK- or anti-
IKK- antibodies.
Immunoprecipitation and Immunoblotting—A detailed
description of the technique used for the following experiments
has been previously published (39, 48). Briefly, HD cultures
were rinsed in PBS and the proteins extracted with lysis buffer
(50mMTris-HCl (pH 7.2), 150mMNaCl, l% (v/v) TritonX-100,
1 mM sodium orthovanadate, 50 mM sodium pyrophosphate,
100 mM sodium fluoride, 0.01% (v/v) aprotinin, pepstatin A (4
g/ml), leupeptin (10 g/ml), and 1 mM phenylmethylsulfonyl
fluoride (PMSF)) for 30 min on ice. After adjusting the total
protein concentration, samples were separated by SDS-PAGE
(5, 7.5, or 10% gels) under reducing conditions. For immuno-
precipitation, the extracts were precleared by incubating them
first with 25 l of either normal rabbit IgG serum or normal
mouse IgG serum and Staphylococcus aureus cells, then with
primary antibodies diluted in wash buffer (0.1% Tween 20, 150
mMNaCl, 50 mM Tris-HCl (pH 7.2), 1 mM CaCl2, 1 mMMgCl2,
and 1 mM PMSF) for 2 h at 4 °C, and finally with S. aureus cells
for 1 h at 4 °C. Control immunoprecipitations were performed
by incubating the samples with nonimmune rabbit anti-mouse
IgG alone. S. aureus cells were washed five times with wash
buffer and once with 50 mM Tris-HCl (pH 7.2) and then boiled
in SDS-PAGE sample buffer. Separated proteins were trans-
ferred to nitrocellulose membranes and incubated in blocking
buffer (5% (w/v) skimmedmilk powder in PBS, 0.1% Tween 20)
for 1 h at AT. Membranes were incubated with the primary
antibodies (Cbfa-1, TRAP, Sirt-1, p65, IB, p-IB, and -ac-
tin, and diluted in blocking buffer, overnight at 4 °C), washed
three times with blocking buffer, and then incubated with the
secondary antibody conjugated with alkaline phosphatase for
90min at AT.Membranes were rinsedwith blocking buffer and
thenwashed three times in 0.1MTris (pH9.5) containing 0.05M
MgCl2 and 0.1 M NaCl. Specific antigen-antibody complexes
were rendered visible using nitro blue tetrazolium and 5-bro-
mo-4-chloro-3-indolyl phosphate (p-toluidine salt; Pierce) as
the substrates for alkaline phosphatase. Total protein concen-
trationwas determined according to the bicinchoninic acid sys-
tem (Pierce) using bovine serumalbumin as a standard. Specific
binding was quantified by densitometry using “Quantity One”
(Bio-Rad).
p65 Acetylation Assay—p65 lysine acetylation was analyzed
by immunoprecipitation of p65 followed by Western blotting
using acetyl-lysine antibodies. Cells were treated with 5M res-
veratrol for 4 h and then exposed to 10 nM RANKL for the
indicated times. Whole cell extracts were prepared, immuno-
precipitated with an anti-p65 antibody, and subjected toWest-
ern blot analysis using an anti-acetyl-lysine antibody.
Statistical Analysis—Numerical data are expressed as mean
values (S.D.) for a representative experiment performed in
triplicate. The means were compared using Student’s t test
assuming equal variances. Differences were considered to be
statistically significant if the p value was less than 0.05.
RESULTS
Cell Culture—Explants of canine bone (about 3–5mm) were
cultured in a flask with growth medium. After 1–2 weeks, bone
tissue cells migrated from the bone tissue, adhered to the cul-
ture flask, and formed a monolayer (data not shown). This
monolayer was passaged 2–3 times to gain sufficient cells for
the preparation of high density cultures. Using a well estab-
lished model of osteogenesis (high density culture), the effects
of resveratrol on RANKL-inducedNF-B signaling pathway on
bone-derived cells were determined.
Resveratrol Inhibits RANKL-induced Osteoclastogenesis—
To observe the osteogenic potential of the bone-derived cells in
an environment as close to the in vivo situation as possible,
primary osteoblasts were transferred to three-dimensional sur-
roundings in high density culture. Transmission electron
microscopy was used to obtain high resolution images from the
high density cultures after 14 days to evaluate cellular ultra-
structure and extracellular matrix formation (Fig. 1).
In the untreated high density cultures, osteogenesis was
observed in primary bone-derived cell cultures (Fig. 1a, panels
A–D). Cells exhibited high levels of euchromatin in their nuclei,
a large number of morphologically normal cellular organelles
(mitochondria, rough ER, andGolgi apparatus), numerous cell-
cell processes, and large quantities of thick fibrils of well orga-
nized extracellular matrix.
On the 1st day in culture, bone-derived cells made intimate
contact and exhibited large, mostly euchromatic nuclei and a
rounded shape. Cell organelles such as rough ER, mitochon-
dria, granules, and vesicles became visible (data not shown). On
day 3, cells exhibited amore spindle-like shape and increasingly
detached from each other (Fig. 1a, panel A). Cells had an irreg-
ular, elongated, and darkly stained nucleus and intercellular
spaces widened. Cell organelles were clearly visible, i.e. rough
ER, free ribosomes, Golgi apparatus, glycogen granules, and
vesicles. Cells developed many microvilli-like and sheet-like
cytoplasmic processes. By means of these processes, cells
remained in contact with neighboring cells. The first indication
of an extracellular matrix was in the immediate pericellular
space near the cellmembrane (Fig. 1a, panel A). On day 7,many
bundles of extracellular matrix fibrils were clearly visible in the
newly formed extracellular matrix (Fig. 1a, panel B). Extracel-
lular matrix fibrils formed bundles of parallel oriented fibrils.
Fibril bundles made contact with cell membranes, and fibrils
increased more and more from day 10 onward (Fig. 1a, panel
C). On day 14, intercellular spaces widened further and con-
tained much more matrix. Typically cross-striated collagen
fibrils, which had tight contact to the cell membrane, were vis-
ible, some of them arranged in bundles along the osteocytes
others oriented more transversally (Fig. 1a, panel D).
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To investigate the effect of RANKLon osteoclastogenesis, we
used a culture systemwhere bone-derived cellswere cultured in
a three-dimensional high density system in the presence of
RANKL and/or resveratrol. In contrast to untreated cultures,
high density cultures of bone tissue cells treated with RANKL
were completely differentiated to osteoclasts-like cells (Fig. 1a,
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panels E–H). After 3 days of treatment, an extensive breakdown
of bone matrix was observed, whereby the cell membrane
detached from the matrix and a space developed between cell
membrane and matrix. The bone-derived cells themselves
responded to RANKL treatment with certain changes in their
shape. Some cells became flat, initially assumed a polygonal
shape and later took on an elongated shape, showed some pro-
cesses, and some of them developed rounded cells (Fig. 1a,
panel E). After 4–7 days, multinucleated osteoclasts were
observed. Depending on its localization, the matrix was differ-
ently affected. Initially, the pericellular matrix was degraded;
later on the entire matrix was affected (Fig. 1a, panel F). After
10 and 14 days of RANKL treatment in high density cultures,
the number of bone-derived cells showing the above-men-
tioned changes had increased, and completely degradedmatrix
could be found (Fig. 1a, panels G and H).
Because RANKL signaling is critical for osteoclastogenesis,
resveratrol effect on RANKL-induced osteoclastogenesis in
high density cultures was examined. Bone-isolated cells were
incubated with resveratrol (5 M) for 4 h and then co-treated
with RANKL (10 nM) and 5 M resveratrol for the indicated
time. As shown in Fig. 1a, panels I–L, resveratrol significantly
inhibited RANKL-induced differentiation of osteoclasts. Pre-
treatmentwith resveratrol resulted inwell developed osteoblast
cultures with viable cells and well developed and organized cell
organelles. The cells formed a dense and regular extracellular
matrix (Fig. 1a, panels I–L). In addition, the number of oste-
oclasts decreasedwith increasing incubation timewith resvera-
trol (Fig. 1b).
Demonstration of Collagen Type I and Osteocalcin in High
Density Cultures Treated with or without RANKL by Immuno-
electronMicroscopy—To further characterize the quality of the
extracellular matrix produced, immunoelectron microscopy
was employed, and cultureswere immunolabeledwith antibod-
ies against collagen type I (Fig. 1c, panels A and B), which is the
most abundant collagen type found in bone matrix and osteo-
calcin, a bone matrix-specific proteoglycan (Fig. 1c, panels C
and D). High levels of collagen type I expression were con-
firmed in untreated high density cultures and cultures pre-
treated with resveratrol and then co-treated with RANKL after
7 days (Fig. 1c, panels A and B); abundant quantities of gold
particles could be observed directly on the bundles of thick
extracellular matrix fibrils. Furthermore, strong labeling for
osteocalcin was observed in untreated isolated bone tissue cul-
tures and cultures pretreated with resveratrol and then
co-treated with RANKL (Fig. 1c, panels C and D). As expected
for osteocalcin, gold particles were clustered together indicat-
ing existence of osteocalcin between the mesh of the collagen
fibers as is typical for proteoglycan distribution in extracellular
matrix. Labeling of RANKL-treated cultures was not per-
formed as it had occurred without matrix formation.
In High Density Culture of Bone-isolated Cells, RANKL
Induced Osteoclastogenesis, but IL-1 Induced Apoptosis—To
test and compare the results performed with RANKL-treated
bone-isolated cells, the same investigations were performed in
high density culture with IL-1-treated bone-isolated cells as a
negative control and finally analyzed with electronmicroscopy.
Treatment with RANKL resulted inwell developedmultinucle-
ated osteoclast-like cells with viable cells and well developed
and organized cell organelles (Fig. 2,A–F). As further shown in
Fig. 2, bone-derived cells underwent apoptosis when treated
with IL-1 (10 ng/ml) for 10 days (Fig. 2J). IL-1-treated bone-
derived cells showed degenerative changes such as swelling of
rough ER and clustering of swollen mitochondria and degener-
ation of other cell organelles. After longer incubation periods
(15–20 days), more severe features of cellular degeneration
were seen in response to IL-1 treatment (Fig. 2, K and L).
These include areas of condensed heterochromatin in the cell
nuclei. The bone-derived cells became more and more
rounded, lost their microvilli-like processes, produced no
matrix, and underwent apoptosis, the characteristic morpho-
logical features of this process being membrane blebbing, dis-
integration of the nucleus, chromatin condensation along the
nuclear envelope, and the presence of apoptotic bodies (Fig. 2,
K and L).
Resveratrol Inhibits RANKL-induced Osteoclastogenesis—
Next, we examined the effects of resveratrol on RANKL-in-
duced osteoclastic differentiation of bone-derived cells. The
bone-derived cells cultured in the absence of RANKL failed to
differentiate into TRAP-positive osteoclasts (Fig. 3a, panels
A–D), but 3 days of treatment with 5 nM RANKL dramatically
changed themorphology of cells and resulted in the appearance
of TRAP-positive osteoclast-like cells (Fig. 3a, panels E–H).
TRAP immunofluorescence staining at day 3 of RANKL stim-
ulation revealed the presence of multinucleated TRAP-positive
osteoclast-like cells (Fig. 3a, panels E–H), whereas unstimu-
lated control cells (Fig. 3a, panels A–D) and pretreated cells
(Fig. 3a, panels I–L) with resveratrol remained mononuclear
and TRAP-negative. Statistical analysis demonstrated that
RANKL-stimulated cultures displayed significantly higher
TRAP activity 3, 7, 10, and 14 days of culture compared with
control cells (Fig. 3b). In contrast, resveratrol reduced the for-
mation of TRAP-positive osteoclasts in a concentration- and
time-dependent manner (Fig. 3b). As little as 1 M resveratrol
had a significant effect on RANKL-induced TRAP-positive
osteoclast formation. Complete inhibition of osteoclastogen-
esis was observed at 5 M resveratrol concentration. Nonethe-
FIGURE 1. Cultivation of primary isolated bone tissue cells in high density culture. Resveratrol inhibited RANKL-induced osteoclastogenesis. a, bone-
derived cells (1  106 cells) were incubated in high density culture with or without RANKL (10 nM) and with or without 5 M resveratrol for 14 days before
evaluation by transmission electron microscopy. Os, osteoblast; MNC, multinucleated cells; arrow, extracellular matrix. Magnification, 5000; bar  1 m.
b, multinucleated osteoclasts (those containing 2–3 nuclei) were counted. c, cells exposed to medium alone (control). c, immunoelectron microscopy. Collagen
type I and osteocalcin in the matrix of untreated (panel A) and pretreated primary isolated bone tissue cells cultures (panel B) abundant amounts of collagen
type I were detected. Secondary gold particle-labeled antibody was observed directly on the bundles of thick extracellular matrix fibrils. In the matrix of
untreated (panel C) and pretreated primary isolated bone tissue cells cultures (panel D), abundant amounts of osteocalcin were confirmed. Secondary gold
particle-labeled antibodies clustered together indicating the existence of osteocalcin between the mesh of the collagen fibers. The quantity and distribution
of gold particles was similar between untreated and precultures. Magnification 24,000; bar, 0.25 m; Os, osteoblast.
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less, the viability of cells under these conditions was not
affected at the concentrations used in this study.
Resveratrol Suppresses RANKL-induced Expression of Oste-
oclasticMarker (TRAP) inHighDensityCultures—Toconfirm the
immunohistological results,weexaminedtheexpressionofTRAP,
as it is anearlymarker forosteoclastic lineagecommitment (49),by
immunoblottingassay. Inuntreatedculturesofbone-derivedcells,
TRAP was not detected in high density cultures (Fig. 4). In con-
trast, in bone-derived cell cultures treated with RANKL,
TRAP expression was significantly increased in a time-de-
pendent manner (Fig. 4). Furthermore, in pretreated cul-
tures with resveratrol and then co-treated with RANKL,
TRAP was not detectable (Fig. 4).
Resveratrol Suppresses RANKL-induced NF-B Activation—
To determine the effect of resveratrol on RANKL-induced
NF-B activation in bone-derived cells, we investigated the
NF-B signaling pathway. Cells were either pretreatedwith res-
veratrol for 4 h or left untreated, followed by 5 nMRANKL for 0,
10, 20, 30, 40, and 60 min in monolayer cultures. Whole cell
lysates, cytoplasmic extracts, and nuclear extracts were taken at
various time points and evaluated byWestern blotting. As dem-
onstrated in Fig. 5A, RANKL clearly induced the translocation
FIGURE 2. RANKL-induced osteoclastogenesis in bone cells but IL-1-induced apoptosis. Bone-derived cells (1  106 cells) were incubated in high density
culture with RANKL (10 nM) or with IL-1 (10 ng/ml) for 20 days and then evaluated by transmission electron microscopy. Os, osteoblast; MNC, multinucleated
cells; arrow, extracellular matrix. Magnification 5000; bar, 1 m.
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of NF-B in the nucleus in a time-dependent manner. As
shown, the activation of NF-B by RANKL was time-depen-
dent. Furthermore, the activation ofNF-B induced by RANKL
FIGURE 4. Resveratrol inhibits RANKL-dependent expression of TRAP in
high density cultures. Bone-derived cells (1  106 cells) in high density cul-
ture were incubated either alone (control) or treated with RANKL (10 nM) for
different times alone or pretreated with resveratrol (5 M) for 4 h and then
co-treated with 10 nM RANKL for the same time period indicated above.
Whole cell extracts were prepared, and cell lysates were resolved by SDS-
PAGE, electrotransferred to nitrocellulose membrane, and then probed for
TRAP expression by Western blot analysis using antibodies to this protein.
-Actin served as an internal control. TRAP control peptide (Co Pep) was used
as a control.
FIGURE 5. Resveratrol suppresses RANKL-induced NF-B activation in a
time- and dose-dependent manner. A, bone-derived cells (1  106 cells) in
monolayer culture were either untreated controls (left panel) or treated with
resveratrol (5 M) for 4 h and with 10 nM RANKL for the indicated times (right
panel). Nuclear extracts were prepared and assayed for NF-B activation by
Western blot analysis as described under “Experimental Procedures.” B, bone
cells (1  106 cells) in monolayer cultures either alone (left panel) or preincu-
bated with the 5 M resveratrol for 4 h were treated with the indicated con-
centrations of RANKL for 50 min. Nuclear extracts were prepared and assayed
for NF-B activation by Western blot analysis as described under “Experimen-
tal Procedures.” Synthesis of poly(ADP-ribose) polymerase (PARP) remained
unaffected in nuclear extracts.
FIGURE 3. Resveratrol inhibits RANKL-induced osteoclastogenesis. a, bone-derived cells (1  106 cells) were incubated in high density culture with or
without RANKL (10 nM) and with or without the indicated concentrations of resveratrol for 14 days and then immunostained for TRAP expression. Control was
for cells exposed to medium alone (control). TRAP-positive cells were photographed (original magnification, 40). b, TRAP-positive multinucleated osteoclasts
were counted. Data represent the mean of three measurements. C, control.
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was clearly suppressed in resveratrol-pretreated cells (Fig. 5A).
To determine whether resveratrol blocks RANKL-induced
activation of NF-B in a concentration-dependent manner by
higher concentrations of RANKL, resveratrol-pretreated and
-untreated cells were co-treated with different concentrations
of RANKL for 50 min.
Nuclear extracts were prepared and analyzed for NF-B
activation by Western blotting. At a concentration of 30 nM,
RANKL caused the maximum NF-B activation in bone-de-
rived cells. Resveratrol pretreatment, however, significantly
suppressed the activation induced by either concentration of
RANKL (Fig. 5B). Unlike Fig. 5A, however, the suppression
of NF-B activation induced by 10 nM RANKL was not
complete.
Resveratrol Suppresses RANKL-induced IBDegradation in
Bone-derived Cells in Vitro—It is known that activation of
NF-B requires degradation of its inhibitory subunit IB (50).
Bone-derived cells were incubated with RANKL (10 nM) either
alone or in the presence of resveratrol (5 M) for the indicated
times. Cytoplasmic extractswere prepared, fractionated by 10%
SDS-PAGE, and transferred to nitrocellulose membranes. To
identify the mechanism by which resveratrol is involved in the
inhibition of RANKL-induced NF-B activation, IB expres-
sion was analyzed by Western blot analysis. In untreated con-
trol cells, IB expression decreased within 10 min after treat-
ment with RANKL but returned to normal expression again
within 60 min (Fig. 6A, left panel). Opposite to that, RANKL-
induced IB degradation was completely suppressed in cells
pretreated with resveratrol (Fig. 6A, right panel). Synthesis of
the housekeeping protein -actin remained unaffected, indi-
cating that the effect was specific (Fig. 6A).
Resveratrol Suppresses RANKL-induced IB Phosphor-
ylation—To test whether resveratrol is able to block the
RANKL-induced phosphorylation of IB, serum-starved
bone-derived cells were treated with RANKL for 1 h and exam-
ined by Western blot analysis using an antibody that is able to
recognize the phosphorylated form of IB. It is known that
phosphorylation of IB leads to its degradation (50), and the
phosphorylation and degradation of IB were inhibited by a
specific proteosome inhibitor N-Ac-Leu-Leu-norleucinal (39).
As shown byWestern blot analysis in Fig. 6B, RANKL was able
to phosphorylate IB in cells pretreatedwith the inhibitor; the
phosphorylation of IB was significantly higher compared
with control cells. Interestingly, resveratrol was able to inhibit
the phosphorylation of IB induced by RANKL in the pres-
ence or absence of the inhibitor (Fig. 6B).
Resveratrol Suppresses RANKL-induced IKK Activation—
Resveratrol sustained RANKL-induced phosphorylation of
IB by inhibition of proteasome function. Therefore, we
determined the effect of resveratrol on RANKL-induced IKK
activation, which is required for phosphorylation of IB.
Immunocomplex kinase assays of bone-derived cells treated
with RANKL clearly showed an IKK activity, as indicated by the
phosphorylation of GST-IB within 5 min. In contrast, as
shown in Fig. 6C, cells pretreated with resveratrol completely
suppressed RANKL-induced activation of IKK. To see
whether the decrease of IKK activity was because of the
decrease of IKK protein expression, the levels of the IKK
subunits IKK- and IKK- were analyzed by Western blot-
ting. RANKL or resveratrol had no direct effect on the
expression of IKK proteins (Fig. 6C).
RANKL-mediated p300 Expression—Transcriptional co-ac-
tivators such as p300 (acetyltransferase) play critical roles in
transcriptional activation (19, 20). However, the effect of
RANKL on p300 function during osteoclastogenesis has not
been investigated. We investigated whether the effects of
RANKL on NF-B are mediated by p300. It is now commonly
accepted that p300 protein displays acetyltransferase activity
that transfers an acetyl group to the -amino group of lysine
residues located in histone or non-histone proteins (20).
To assess the involvement of the RANKL in p300 signaling,
we used an anti-p300 antibody in immunoblot experiments to
identify p300 in RANKL-treated bone-derived cells. In bone-
derived cell cultures treated with RANKL, p300 expression was
significantly increased in a time-dependent manner (Fig. 7A).
Resveratrol Inhibited Acetylation of p65—To test whether
resveratrol can inhibit acetylation of p65,Western blot analysis
provided evidence that RANKL induces the acetylation of p65,
and furthermore, resveratrol inhibits the RANKL-induced
FIGURE 6. Resveratrol suppresses RANKL-induced IkB degradation (A)
and phosphorylation (B) through inhibition of IKK activity (C). A, bone-
derived cells (1  106 cells) in monolayer culture were incubated with RANKL
(10 nM) either alone (left panel) or in the presence of resveratrol (5 M) (right
panel) for the indicated times. Cytoplasmic extracts were prepared, fraction-
ated by SDS-PAGE, and electrotransferred to nitrocellulose membranes.
Western blot analysis was performed with anti-IB. B, bone cells (1  106
cells) in monolayer culture were preincubated with 100 M N-Ac-Leu-Leu-
norleucinal (ALLN) for 30 min, resveratrol (5 M) for 4 h, RANKL (10 nM) for 30
min, or the indicated combinations. Some cultures were left untreated and
evaluated after 12 h. Cytoplasmic extracts (500 ng of protein per lane) were
fractionated and subjected to Western blotting with phospho-specific IB
antibody. The same membrane was re-blotted with antibodies to -actin.
C, bone cells (1  106 cells) in monolayer culture were incubated with RANKL
(10 nM) either alone (left panel) or in the presence of resveratrol (5 M) (right
panel) for the indicated times. To examine the effect of resveratrol on the
expression level of IKK proteins, whole cell extracts were immunoprecipitated
with an antibody against IB kinase (IKK)- and analyzed by an immune com-
plex kinase assay as described under “Experimental Procedures.” To examine
the effect of resveratrol on the level of IKK proteins, whole cell extracts (500 ng
of protein per lane) were fractionated by SDS-PAGE and examined using
Western blotting with anti-IKK- and anti-IKK- antibodies. Data shown are
representative of three independent experiments.
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acetylation (Fig. 7B). To determine whether resveratrol is able
to block the RANKL-induced acetylation of several proteins,
whole cell lysates from cells treated with RANKL, IL-1, res-
veratrol, or a combination of both of them were analyzed by
Western blot using anti-acetyl-lysine antibody. As shown in
Fig. 7C, RANKL and IL-1 induced acetylation of several pro-
teins, whereas resveratrol suppressed the acetylation of these
proteins.
Resveratrol-activated SIRT-1 (Deacetylase) Inhibits p300
Acetyltransferase andNF-B Signaling—SIRT-1 is amember of
the sirtuin protein family of NAD-dependent deacetylases that
mediates down-regulation of transcriptional activity and pro-
motes cell survival (40–42). Resveratrol has been shown to
activate SIRT-1 deacetylase activity (40). Phosphorylation of
NF-B-p65 is required for its transcriptional regulation, and
acetylation of NF-B-p65 by p300 acetyltransferase plays an
essential role in regulating NF-B signaling (26). Resveratrol-
activated SIRT-1 deacetylase promotes SIRT-1-p300 complex
formation resulting in inactivation of p300 acetyltransferase
and a reduction in the acetylation of NF-B-p65 (51).
To examine the functional impact of SIRT-1 regulation of
RANKL-mediated p300 signaling events (e.g.NF-Bpathways),
cells were cultured in the presence or absence of resveratrol and
in the presence of RANKL, or we pretreated bone-derived cells
with resveratrol and then co-treated themwith RANKL. Treat-
ment of the bone-derived cells with resveratrol alone and pre-
treatment of bone-derived cells with resveratrol and co-treat-
ment with RANKL markedly enhanced the formation of Sirt-1
complexes with p300 (Fig. 8A). To see whether this event
occurs transiently during osteogenesis, we performed the same
experiment with the preosteoblastic cell line (MC3T3-E1). The
results obtained were similar to those with bone-derived cells
(Fig. 8B). This may cause, in part, a significant reduction in
RANKL-induced p300 acetyltransferase activity. It is noted that
RANKL-p300-induced acetylation of NF-B-p65 (Fig. 7B) is
also inhibited by resveratrol. Consequently, transcriptional
activities (mediated by NF-B-p65) are attenuated (Fig. 7).
These findings suggest that resveratrol-mediated activation of
Sirt-1 plays an important role in inhibiting RANKL-activated
p300 acetyltransferase and impairing the NF-B-p65 signaling
cascades during osteoclastogenesis.
Resveratrol Suppresses RANKL-induced Inhibition of Specific
Osteogenic Transcription Factor Cbfa-1 in High Density
Cultures—Next, we examined the osteogenic transcription fac-
tor Cbfa-1 as it is an early marker for osteogenic lineage com-
mitment (29). In untreated or with resveratrol alone-treated
cultures of bone-derived cells, high quantities of Cbfa-1 expres-
sion were detected during osteogenesis in high density cultures
(Fig. 9). In contrast to this, in bone-derived cell cultures treated
with RANKL, Cbfa-1 expression was significantly decreased in
a time-dependent manner (Fig. 9). Furthermore, in pretreated
cultures with resveratrol and then co-treated with RANKL,
Cbfa-1 was detected with enhanced expression (Fig. 9).
FIGURE 7. Analysis of RANKL-mediated p300 expression and resveratrol-
mediated inhibition of RANKL-dependent p65 acetylation in bone-de-
rived cells. A, detection of p300 expression. Bone-derived cells (1  106 cells)
in monolayer culture were incubated with RANKL (10 nM) for the indicated
times and immunoblotted (IB) with anti-p300 antibody or anti-actin antibody
(control). B, effect of resveratrol on RANKL-induced acetylation of p65. Cells
were treated with 5 M resveratrol for 4 h and then exposed to 10 nM RANKL.
Whole cell extracts were prepared, immunoprecipitated (IP) with an anti-p65
antibody, and subjected to Western blot analysis using an anti-acetyl-lysine
antibody. The same blots were reprobed with an antibody to anti-p65.
C, effect of resveratrol on RANKL- or IL-1-induced protein acetylation. Cells
were treated with 5 M resveratrol for 4 h and then exposed to 10 nM RANK or
10 ng/ml IL-1 for 20 min. Whole cell extracts were prepared and subjected to
Western blot analysis using an anti-acetyl-lysine antibody.
FIGURE 8. Analysis of resveratrol-mediated Sirt-1-p300 interaction in
bone-derived cells and preosteoblastic MC3T3-E1 cells. Bone-derived
cells (1  106 cells) and the preosteoblastic cell line (1  106 cells) in mono-
layer culture were either left untreated or treated with 5 M resveratrol (Res)
alone or treated with 10 mM RANKL alone for 3 days or pretreated with 5 M
resveratrol for 4 h and then exposed to 10 nM RANKL for 3 days. Cell lysates
were immunoprecipitated (IP) with anti-p300 antibody followed by immuno-
blotting with anti-SIRT-1 antibody or reblotted with anti-p300 antibody (as a
loading control (Co)).
Resveratrol Inhibits Osteoclastogenesis




























Resveratrol Suppresses RANKL-induced Inhibition of Sirt-1 in
High Density Cultures—To show the possible mechanism for
Cbfa-1 activation by resveratrol, cells were cultured in the pres-
ence or absence of resveratrol and in the presence of RANKL, or
we pretreated bone-derived cells with resveratrol and then co-
treated them with RANKL. As shown in Fig. 10, in untreated
cells and with resveratrol-treated cells, the expression of Sirt
increased in high density cultures. In contrast, when cells were
treated with 10 nM RANKL, the expression of endogenous
Sirt-1 was decreased. Interestingly, resveratrol pretreatment
caused significant Sirt-1 up-regulation (Fig. 10).
Association of Sirt-1 Proteins with the Early Osteogenic Tran-
scription Factor Cbfa-1 by Resveratrol in Osteoblasts—To
determine possible downstream signaling proteins in osteo-
blasts, we examined whether Sirt-1 associates with the early
osteogenic transcription factor Cbfa-1 and subsequently acti-
vates the pathway that stimulates osteogenesis. To this end,
cells were cultured in the presence or absence of resveratrol,
lysed, and immunoprecipitated with anti-Sirt-1 or with anti-
Cbfa-1 antibodies. The anti-Sirt-1 immunoprecipitates were
then immunoblotted with anti-Cbfa-1 antibodies, and the anti-
Cbfa-1 immunoprecipitates were then immunoblotted with
anti-Sirt-1 antibodies. Interestingly, anti-Sirt-1 and anti-
Cbfa-1 immunoprecipitates from resveratrol-stimulated but
not from unstimulated cultures revealed that the Sirt-1 protein
co-immunoprecipitated with the osteogenic transcription fac-
tor Cbfa-1 protein (Fig. 11, I and II).Moreover, the same immu-
noprecipitates were reblotted with anti-p300 antibody and
showed a complex formation with p300-Sirt-1-Cbfa-1 (Fig. 11,
III). Taken together, these results indicate that during osteo-
genesis resveratrol activates Sirt-1 and induces Sirt-Cbfa-1
complex formation, which activates the osteogenic pathway.
DISCUSSION
The purpose of this study was to investigate the effects of
resveratrol on RANKL-induced NF-B activation and on oste-
oclastogenesis in primary isolated bone cells. Using the well
established high density culture system for osteoclastogenesis
and osteogenesis, we found that resveratrol inhibited RANKL-
induced NF-B activation through the suppression of IB
phosphorylation, IB degradation, and IB kinase activity,
thereby preventing multinucleated osteoclast formation.
Moreover, we also found that resveratrol activates the bone
tissue cells to osteoblast and osteogenesis through activation of
the osteogenic transcription factor Cbfa-1 and NAD-depen-
dent acetylase enzyme Sirt-1.More interestingly, we found that
Sirt-1 associated with the Cbfa-1, enhancing transcription of
bone specific collagen type I in a Cbfa-1-dependent fashion.
Resveratrol is a naturally occurring polyphenol, and it has
been shown to exhibit anti-inflammatory and anti-oxidant
effects in various cell types and has been suggested to have
therapeutic potential for treatment of various diseases, includ-
ing osteoporosis (52). Osteoporosis is characterized by a nega-
tive balance of bone metabolism, which leads to a decreased
bone mass with subsequent thinning of the trabecular and cor-
tical bone and a significantly greater risk of bone fractures (3).
Therefore, it is of critical interest to study the mechanism by
which resveratrol activates osteoblasts. It has been reported
that resveratrol acts as a phytoestrogen and may exhibit vari-
able degrees of estrogen receptor agonism (52). The similarity
in structure between resveratrol and the synthetic estrogen
FIGURE 9. Effects of resveratrol on RANKL-induced inhibition of Cbfa-1
production in bone cells. High density bone-derived cell cultures were
either untreated or treated with 10 nM RANKL alone or with 5 M resveratrol
(Res) alone or pretreated with 5 M resveratrol for 4 h and then cotreated with
10 nM RANKL for the indicated times. To evaluate the effects of resveratrol on
RANKL-stimulated osteogenic inhibition in cultures, whole cell lysates (500
ng of protein per lane) were fractionated and then subjected to Western
blotting with antibodies to the specific osteogenic transcription factor
Cbfa-1. Synthesis of the housekeeping protein -actin was unaffected.
FIGURE 10. Effects of resveratrol on RANKL-induced inhibition of Sirt-1
production in bone tissue cells. High density bone cell cultures were either
untreated or treated with 10 nM RANKL alone or with 5 M resveratrol alone or
pretreated with 5 M resveratrol for 4 h and then cotreated with 10 nM RANKL
for the indicated time periods. To evaluate the effects of resveratrol on
RANKL-stimulated osteogenic inhibition in cultures, whole cell lysates (500
ng of protein per lane) were fractionated and subjected to Western blotting
with antibodies to Sirt-1. Synthesis of the housekeeping protein -actin was
unaffected. Sirt-1 control peptide (Co Pep) was used as a control.
FIGURE 11. Interaction of Sirt-1 with Cbfa-1 and p300 by resveratrol, as
revealed by a co-immunoprecipitation assay. Cells were cultured in the
presence or absence of resveratrol, lysed, and immunoprecipitated (IP) with
anti-Sirt-1 or with anti-Cbfa-1 antibody. The immunoprecipitates were sepa-
rated by SDS-PAGE and analyzed by immunoblotting using anti-Sirt-1 and
anti-Cbfa-1 antibodies or reblotted with anti-p300 antibody (as a loading
control). Results shown are representative of three independent experi-
ments. IgH, immunoglobulin heavy chain.
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diethylstilbestrol encouraged the investigators, and it was the
basic hypothesis of this study to see whether resveratrol might
exhibit estrogenic activity, a property that is known to produce
a protective benefit in osteoporosis (53).
In this study, we investigated the effects of resveratrol on
osteogenesis and bone metabolism and therefore we employed
monolayer and high density in vitromodels of bone tissue con-
sisting of three different cell types as follows: osteoblasts and
osteocytes, preosteoclasts, and undifferentiated mesenchymal
cells. This cell population of bone tissue showed the direct
effect of RANKL on osteoclast formation and allowed us to
focus on the process of RANKL signaling in preosteoclasts.
The results indicate that RANKL induces NF-B activation
in osteoclastic cells through the activation of IKK and the sub-
sequent phosphorylation and degradation of IB, a finding
that is in complete agreement with previous in vitro studies
(54). Furthermore, our results indicate that resveratrol abol-
ishes the RANKL-induced IKK activation that is required for
the phosphorylation of IB (50). Indeed, it has been recently
shown that IKKs aremajor regulators of cytokine-induced oste-
oclastogenesis and inflammatory arthritis (55).
It has already been shown that NF-B signaling plays an
important role in osteoclastogenesis (56). RANKL activates
NF-B through the cell surface receptor RANK during oste-
oclastogenesis. Indeed, in double knock-out mice with NF-B
p50/ and p52/, heavy osteopetrosis was caused by the fail-
ure of osteoclast formation (57, 58). This is an example that
shows NF-B p50 and p52 expression are necessary for the
differentiation of RANK-expressing preosteoclast or osteoclast
precursors into TRAP-positive osteoclasts in response to
RANKL and other osteoclastogenic cytokines (59). It is known
that NF-B is activated after interaction between RANKL and
RANK. Furthermore, osteoclast differentiation is inhibited by
osteoprotegerin, which binds to RANKL and thereby prevents
its interaction with RANK (60).
Several studies have already reported that NF-B is activated
by RANKL in different cell types (16, 61) and that it is required
for osteoclast formation in vivo (57). Therefore, suppression of
NF-B activation might play an essential role during osteoclas-
togenesis. Interestingly, in this study, we note that suppression
of NF-B activation by resveratrol correlated with inhibition of
osteoclastogenesis indicating that NF-B activation is critical
for RANKL-induced osteoclastogenesis.
As a phytoestrogen, resveratrol, is a potent activator of Sirt-1
deacetylase activity. In this study, we found that both p300
acetyltransferase and Sirt-1 deacetylase are expressed in bone-
derived cells. In addition, we have shown that RANKL activates
p300 acetyltransferase activity. Our results also demonstrate
FIGURE 12. A schematic model illustrating the effects of resveratrol on bone-derived cells and the mechanisms by which RANKL regulates osteoclast
differentiation and function.
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that RANKL-activated p300 acetyltransferase serves as a potent
transcriptional regulator by acetylating NF-B-p65. In fact, it
has been reported that acetylation of RelA (p65) at lysine 310 is
regulated by prior phosphorylation of serine 276 and 536. Fur-
thermore, the phosphorylated and acetylated RelA displays
enhanced transcriptional activity (26). Our results indicate that
resveratrol may suppress RANKL-induced p65 acetylation
through inhibition of histone acetyltransferase activity. In con-
trast, resveratrol-activated Sirt-1 deacetylase promoted Sirt-1-
p300 complex formation during osteogenesis resulting in inac-
tivation of p300 acetyltransferase and a reduction in the
acetylation of NF-B-p65 (Fig. 7B). These results highlight a
novel functional interaction between RANKL-activated p300
acetyltransferase and phytoestrogen resveratrol-activated
Sirt-1 deacetylase during the regulation of acetylation versus
deacetylation states of NF-B-p65 in osteogenesis/osteoclasto-
genesis. Consequently, whether acetylation (or deacetylation)
of NF-Bmodulates their functions during osteoclastogenesis/
osteogenesis is a very important issue.
We also observed activation of the specific osteogenic tran-
scription factor Cbfa-1 as a marker for osteogenic activity.
Cbfa-1 is the earliest and most specific marker of osteogenesis
(29). It has been shown that Cbfa-1 acts as an activator of tran-
scription and can induce osteoblast-specific gene expression in
fibroblasts and myoblasts in culture (29). Therefore, we exam-
ined the effect of resveratrol on the Cbfa-1 activity of bone-
derived cells. In this study, Cbfa-1 activation was observed in
control cells and resveratrol-treated primary isolated bone
cells. Resveratrol dose-dependently increased Cbfa-1 activity
and seemed to stimulate the proliferation and differentiation of
osteoblasts.
In contrast, RANKL blocked the expression of Cbfa-1 in
bone cells, and this was clearly inhibited by the presence of
resveratrol. Therefore, these results suggest that resveratrol
increases bone formation, at least in part, by Cbfa-1 activation.
The inhibitory effect of resveratrol on RANKL-induced Cbfa-1
activation in osteoblastic cells may lead to the inhibition or
differentiation from preosteoclastic cells and stem cells to oste-
oclasts and the stimulation of mineralization.
Finally, resveratrol is one of themost potent Sirt-1 activators.
By binding to an as yet undefined binding site, it induces a
conformational change in Sirt-1, inducing the acetylated sub-
strate and NAD, resulting in an increased enzymatic activity
(40). Furthermore,many Sirt-1 substrates are transcription fac-
tors and key regulators known to participate in embryonic
growth and in neoplasia (i.e. the tumor suppressor gene p53,
the nuclear factor-B (NF-B), the DNA repair factor Ku70,
and the longevity-associated forkhead transcription factors
(FoxOs) (62)).However, the relationship between Sirt-1 activity
and osteogenesis is not fully elucidated and is still open to
debate. Our results demonstrate clearly that the Sirt-1 protein
is expressed in bone cells and is further stimulated in cultures
treated with resveratrol. Sirt-1 has no inherent DNA binding
ability, and it was thought that its effect ismediated through the
Cbfa-1 transcription factor, which regulates expression of
many bone-specific genes (29). In our study, co-immunopre-
cipitation experiments demonstrated that the two proteins
associate in vitro. Consistent with this observation, Sirt-1
appears to deacetylate Cbfa-1 and thus Sirt-1 contributes to the
maintenance of the osteoblast phenotype by direct regulation
of factors such as Cbfa-1. Therefore, Cbfa-1 appears similar to a
growing number of other transcription factors, such as p53,
NF-B, MyoD, and FOXO, in that it can be modified by
acetylation/deacetylation.
In conclusion, this study has provided important insights
into the mechanisms by which RANKL-activated p300 func-
tions andmodulatesNF-B signaling, aswell as how their target
genes regulate osteoclastogenesis. We have further demon-
strated that resveratrol can exert anti-osteoclastogenic effects,
which is most likely mediated through the suppression of
RANKL-p300-NF-B activation (see the illustration in Fig. 12).
These results provide the theoretical basis for a novel approach
to treating osteoporosis and rheumatoid-related bone lesions
using resveratrol and structurally related compounds. How-
ever, further studies are needed to understand the mechanistic
details. For example, the cellular mechanism of action of Sirt-1
in resveratrol-mediated osteogenesis demands further investi-
gation using appropriate in vivo models. Resveratrol may
become a useful adjunct in the prevention and treatment of
osteoporosis.
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Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., Shimamoto,
G., DeRose, M., Elliott, R., Colombero, A., Tan, H. L., Trail, G., Sullivan, J.,
Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T. M., Hill, D., Pattison,
W., Campbell, P., Sander, S., Van, G., Tarpley, J., Derby, P., Lee, R., and
Boyle, W. J. (1997) Cell 89, 309–319
18. Pettit, A. R., Ji, H., von Stechow, D., Müller, R., Goldring, S. R., Choi, Y.,
Benoist, C., and Gravallese, E. M. (2001) Am. J. Pathol. 159, 1689–1699
19. Bannister, A. J., and Kouzarides, T. (1996) Nature 384, 641–643
20. Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H., and Nakatani,
Y. (1996) Cell 87, 953–959
21. Janknecht, R., and Hunter, T. (1996) Nature 383, 22–23
22. Sterner, D. E., and Berger, S. L. (2000) Microbiol. Mol. Biol. Rev. 64,
435–459
23. Kiernan, R. E., Vanhulle, C., Schiltz, L., Adam, E., Xiao, H., Maudoux, F.,
Calomme, C., Burny, A., Nakatani, Y., Jeang, K. T., Benkirane,M., andVan
Lint, C. (1999) EMBO J. 18, 6106–6118
24. Gu, W., and Roeder, R. G. (1997) Cell 90, 595–606
25. Martínez-Balbás, M. A., Bauer, U. M., Nielsen, S. J., Brehm, A., and Kou-
zarides, T. (2000) EMBO J. 19, 662–671
26. Chen, Lf., Fischle, W., Verdin, E., and Greene, W. C. (2001) Science 293,
1653–1657
27. Graham, B., and Gibson, S. B. (2005) Cell Cycle 4, 1342–1345
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